Connect with us
Information

WORLD EDITION
Australia
North America
World

Investing News NetworkYour trusted source for investing success

WORLD EDITION
North America
Australia
World
My INN

Private Placements

Reports & Guides
- Market Outlook Reports
- Investing Guides
Button

Precious Metals
Battery Metals
Base Metals
Energy
Critical Minerals

Biotech Market
Biotech News
Biotech Stocks

Home
Life Science Investing Biotech Investing

immix biopharma

immix biopharma

NCM:IMMX

Immix Biopharma

Chart

Detailed Quote

Immix Biopharma Inc is a clinical-stage biopharmaceutical company developing Tissue-Specific Therapeutics in oncology and inflammation.

Featured Articles and Interviews

row of test tubes and pipette with chemical droplet chemical coming from it

Dec 12, 2023

Top 5 NASDAQ Biotech Stocks (Updated December 2023)

Press Releases

May 22, 2026

Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock

May 21, 2026

Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock

May 21, 2026

Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2

See More Press Releases

The Conversation (0)

Alert Options

No alert set

INN Article Notification

Instant Daily Weekly

Alert Option

You will be notified when this event occurs. No additional settings needed.